Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter

The nuclear factor-κB (NF-κB) is known to be activated in many cancer types including lung, ovarian, astrocytomas, melanoma, prostate as well as glioblastoma, and has been shown to correlate with disease progression. We have cloned a novel NF-κB-based reporter system (five tandem repeats of NF-κB re...

Full description

Saved in:
Bibliographic Details
Main Author: Zalloua, P. A. (author)
Other Authors: Tannous, B. A. (author), Badr, C. E. (author), Niers, J. M. (author), Morse, D. (author), Koelen, J. A. (author), Vandertop, P. (author), Noske, D. (author), Wurdinger, T. (author)
Format: article
Published: 2011
Online Access:http://hdl.handle.net/10725/4823
http://dx.doi.org/10.1038/gt.2010.1562
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
http://www.nature.com/gt/journal/v18/n5/abs/gt2010156a.html
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The nuclear factor-κB (NF-κB) is known to be activated in many cancer types including lung, ovarian, astrocytomas, melanoma, prostate as well as glioblastoma, and has been shown to correlate with disease progression. We have cloned a novel NF-κB-based reporter system (five tandem repeats of NF-κB responsive genomic element (NF; 14 bp each)) to drive the expression cassette for both a fusion between the yeast cytosine deaminase and uracil phosphoribosyltransferase (CU) as a therapeutic gene and the secreted Gaussia luciferase (Gluc) as a blood reporter, separated by an internal ribosomal entry site (NF-CU-IGluc). We showed that malignant tumor cells have high expression of Gluc, which correlates to high activation of NF-κB. When NF-κB was further activated by tumor necrosis factor-α in these cells, we observed up to 10-fold increase in Gluc levels and therefore transgene expression in human glioma cells served to greatly enhance the sensitization of these cells to the prodrug, 5-fluorocytosine both in cultured cells and in vivo subcutaneous tumor xenograft model. This inducible system provides a tool to enhance the expression of imaging and therapeutic genes for cancer therapy.